Background: To evaluate the impact of neutrophil-to-lymphocyte ratios (NLR) as a prognostic factor in predicting treatment outcomes after radiotherapy (RT) for solid tumors.
Introduction
Regardless of the advances that have been achieved in modern radiotherapy (RT) techniques, many solid tumors continue to demonstrate unsatisfactory treatment outcomes. Predictive markers for identifying patients with higher risk of unfavorable prognosis are increasingly being emphasized. Several reports have demonstrated that the presence of inflammatory responses in the tumor microenvironment influences cancer development and progression. [1, 2] The relationship of inflammation and cancer involve both chronic inflammatory processes leading to carcinogenesis and intrinsic oncogene mutations that lead to recruitment of inflammatory cells. [3] [4] [5] Various blood sample parameters of systemic inflammation have been investigated for prognostic significance. [2, 6, 7] The neutrophilto-lymphocyte ratio (NLR) is a relatively simple and economical alternative for quantifying subclinical inflammation compared to emerging disease-specific biomarkers that are expensive and take time to obtain results. Increased levels of NLR have shown to be associated with poorer survival in a variety of solid tumors such as colorectal carcinoma, esophageal carcinoma, and non-small cell lung cancer. [6] [7] [8] [9] In terms of its relationship with treatment outcomes in patients that receive RT, however, only a limited number of studies have reported on the potential role of NLR as a predictive factor. Suggestions that high levels of NLR advocate poorer survival have been reported, but the degree of its significance is unclear and data are inconsistent. [10] We thus aimed to evaluate the prognostic value of high levels of NLR in predicting adverse clinical outcomes in patients treated with RT alone or concurrent chemoradiotherapy (CCRT). This systematic review focused on [1] : the general prognostic value of NLR after RT in several solid tumor types and [2] NLR in patients that received RT alone.
Materials and methods

Search strategy
A systematic review of previously documented literature assessing the correlation of NLR and treatment outcomes after RT was performed based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guideline. [11] PubMed, Embase, and Cochrane Library databases were used to search for articles published by February 28, 2019 using the following combination of keywords: "NLR OR neutrophil-to-lymphocyte ratio" AND "cancer OR malignancy" AND "prognosis OR survival OR response" AND "radiotherapy OR radiation therapy."
Study selection
Initial assessment was solely based on the title and abstract of each reference. Full articles of relevant references were then reviewed for eligibility using the following criteria: studies that report outcomes of [1] patients with solid tumors treated with RT with or without concurrent chemotherapy, [2] analyses for prognostic significance of NLR on overall survival (OS), [3] baseline levels of NLR before initiation of RT, and [4] hazard ratios (HR) or informative data that could be used to estimate the HR. Both lab-based and clinical observational studies were included, and prospective studies and randomized controlled trials were excluded because such reports have not yet been presented. Data published only as an abstract, letter, editorial, commentary, review article, or case reports were excluded. Exclusion criteria also included documentations that were not written in English, were not human-based studies, were duplicates, or had overlapping data.
Data extraction
Preliminary database searches and subsequent screening and selection of references were done independently by 2 authors (HCK and NC). Data from eligible studies were extracted using a preset data extraction spreadsheet. The same 2 reviewers assessed all full articles for eligibility. In the case of interreviewer disagreement, consensus was reached after appropriate review. OS was the primary end-point and progression-free survival (PFS), disease-free survival (DFS), distant metastasisfree survival (DMFS), disease-specific survival (DSS), and complete response (CR) were secondary outcomes of interest. Information summarized in the preset included: author, year, and journal of publication; primary site of malignancy; sample size; aim and method of treatment; NLR cut-off value; use of receiver operating characteristic (ROC) curves; HR and 95% confidence interval (CI) for OS, PFS, DFS, DMFS, and DSS; and odd ratio (OR) and 95% CI for CR. In the case of any discrepancy during the process of data extraction and evaluation, a cross-check was performed by a third author (JG) with expertise in biostatistics.
Data synthesis and statistical analysis
This study is a pooled analysis of patients with various cancers of heterogeneous clinical features, inclusion criteria, NLR cut-off values, and study quality. Thus, to reflect the diversity of the selected studies, estimates of the pooled logarithms of the HR (logHR) and its 95% CI were combined using the random-effects model with inverse-variance weighting. I 2 was used to identify and quantify the degree of heterogeneity between the eligible studies included for analysis. [12, 13] Heterogeneity was not considered to be statistically significant if I 2 was <50%. The funnel plot and Egger's linear regression method were used to detect and evaluate publication bias. Survival outcomes were expressed as estimated logHR, using either the reported 95% CI or indirect calculation based on available data. [14, 15] All statistical analysis was performed using RevMan version 5.3 (Cochrane Collaboration, Copenhagen, Denmark).
Results
Study selection
A total of 227 articles were identified through initial database searching. After screening titles and abstracts of identified articles, 38 duplicated articles and 101 articles that were of nonrelevant topics were excluded. Eighty-eight full-text articles were assessed for eligibility. A final of 37 articles were selected, among which 1 article comparing oropharyngeal and nonoropharyngeal head and neck cancers was separated as 2 individual datasets. [16] Thus, a final of 38 datasets with 7065 patients were included for meta-analytic comparison. A schematic flow diagram of the study selection process is depicted in Figure 1 . Table 1 summarizes the characteristics of patients included in the selected studies. All articles were published after 2012 and analyzed OS as the primary endpoint. Analyses included PFS in 15 studies, [10, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] DFS in 11 studies, [16, 17, [31] [32] [33] [34] [35] [36] [37] DMFS in 8 studies, [19, 23, 27, 30, 38, 39] DSS in 1 study, [23] and pathologic CR in 2 studies on preoperative CCRT. [25, 40] The median NLR cut-off value was 3.1 (range 1.9-5.0). ROC curves were used to estimate the optimal NLR cut-off value in 14 studies. [10, [22] [23] [24] [27] [28] [29] 32, 35, 39, [41] [42] [43] [44] Majority included all or locally advanced stages, while 2 studies focused only on early stage cancer. [23, 44] 
Characteristics of included studies
Impact of NLR on OS, PFS, and DFS
The HR for OS was statistically significant on univariate analysis in 34 studies (89.5%), ranging from 1.1 to 7.7 with a median of 2.1. NLR was included in multivariate analyses in 35 studies, among which high NLR retained independently significant prognostic value in 30 studies (85.7%). A forest plot of the pooled analysis including all studies is given in Fig. 2A . Patients with pretreatment NLR greater than the cut-off value demonstrated significantly worse OS (HR 1.90, 95% CI 1.66-2.17, P < .001) with high heterogeneity (I 2 = 74%, P < .001). When including only studies that provided data from multivariate analysis using NLR cut-off values determined by ROC curves (Fig. 2B) , interstudy heterogeneity substantially decreased (I 2 = 18%, P = .25) with no remarkable change of the pooled HR (HR 1.93, 95% CI 1.67-2.24, P < .001).
HRs for PFS was reported in 15 studies with a total of 3537 patients. A pooled analysis for PFS demonstrated a HR of 2.12 (95% CI 1.64-2.75, P < .001) with moderately high heterogeneity (I 2 = 67%, P < .001). DFS was reported in 11 studies for 1750 patients and resulted in a pooled HR of 1.54 (95% CI 1.23-1.94, P < .001), also with moderately high heterogeneity (I 2 = 64%, P < .001). 
NLR and RT alone
Figure 3 provides a forest plot for studies that investigated the effect of NLR in patients receiving RT without the addition of systemic cytotoxic therapy. This included 1697 patients in 9 datasets, consisting of 6 datasets on head and neck cancer [16, 24, 33, 37, 45] and 1 dataset each on prostate cancer, nonsmall cell lung cancer, and pancreatic cancer. [19, 20, 23] The pooled HR for OS was 1.71 (95% CI 1.44-2.04, P < .001) with no interstudy heterogeneity (I 2 = 0%, P = .46) (Fig. 4) .
NLR by disease subsite
Subgroup analyses was done for subsites with the largest number of patients and studies: head and neck (3484 patients in 16 studies), rectum (990 patients in 6 studies), and lung (887 patients in 6 studies). High pretreatment NLR significantly influenced OS by roughtly 2-fold in head and neck cancers (HR 1.91, 95% CI 1.49-2.46, P < .001), 2.5-fold in rectal cancers (HR 2.45, 95% CI 1.47-4.08, P < .001), and 1.5-fold in lung cancers (HR 1.46, 95% CI 1.24-1.72, P < .001). Heterogeneity was low for subgroup analysis of studies on lung cancer (I 2 = 37%, P = .16).
Publication bias
Results of Egger's linear regression test suggested potential publication bias for OS (P < .001). The trim and fill method was used for estimation and adjustment of hypothetically missing studies. The pooled analysis of adjusted data were recalculated, with high NLR demonstrating significantly poorer OS (HR 1.46, 95% CI 1.24-1.71, P < .001). Egger's linear regression test after adjusting with the trim and fill method demonstrated insignificant between-study heterogeneity (P = .461). The funnel plot is given in Figure 5 .
Discussion
This meta-analysis of 38 datasets including 7065 patients demonstrated that high levels of pretreatment NLR is a statistically significant predictor of worse survival outcomes in Figure 1 . Flow chart of study selection. [22, 42, 62] 3 (7.7) 446 (6.0) Esophagus [10, 44, 63] 3 (7.7) 544 (7.3) Prostate [19] 1 (2.6) 415 (5.6) Pancreas [20, 38] 2 (5.1) 273 (3.7) Penis [18] [18, 21, 58] 3 (7.7) 373 (5.0) * 1 was divided into 2 separate datasets (oropharyngeal and nonoropharyngeal head and neck cancer). CCRT = concurrent chemoradiotherapy, NLR = neutrophil-to-lymphocyte ratio, RT = radiotherapy. Data presented as n (%).
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www.md-journal.com patients receiving RT alone or in combination with systemic cytotoxic chemotherapy. All studies included in our study were retrospective observational analyses of various solid tumors and stages. Treatment modality was limited to preoperative or definitive RT alone or in combination with concurrent chemotherapy. Because studies reporting on the relationship between pretreatment NLR and outcomes after RT have been documented in small numbers, this study is limited by the inevitable heterogeneity between studies. However, a pooled analysis of studies reporting OS outcomes based on multivariate analyses and NLR cut-off values determined by ROC curves demonstrated low between-study heterogeneity (I 2 = 18%, P = .25), suggesting meta-analytic stability. Compared to studies focusing on NLR generally in relation to cancer progression, documentation of its impact on clinical outcomes after RT has been reported in relatively low numbers. Our results show that NLR could be of potential prognostic value in predicting worse treatment outcomes in patients receiving either definitive CCRT or RT. Particularly for patients treated by RT alone, the pooled HR for OS was 1.71 (95% CI 1.44-2.04, P < .001) with no betweenstudy heterogeneity (I 2 = 0%, P = .46), suggesting potential clinical significance of NLR as a pretreatment prognostic marker.
The relationship between inflammation and cancer has been widely studied in terms of factors such as pro-inflammatory cytokines and reactive oxygen species that activate transcription factors, which in turn promote the expression of genes that lead to carcinogenesis and cancer progression. [46] [47] [48] Various blood sample parameters have been investigated for prognostic significance in the treatment of several cancers, including high levels of C-reactive protein, interleukins, hypoalbuminemia, anemia, and thrombocytosis. [49] [50] [51] The advantage of ratios such as NLR and platelet-to-lymphocyte ratio is that these values are readily available without the need to perform additional laboratory testing. The use of NLR as a prognostic factor has been studied by several studies in relation to various disease entities and treatment modalities. A meta-analysis by Qi et al [52] demonstrated that low baseline levels of NLR were significantly associated with better survival in patients diagnosed with hepatocellular carcinoma. Furthermore, the authors showed that low NLR levels after treatment completion were also significantly correlated with improved clinical outcomes.
Inflammatory processes, as seen in cancer progression, may have a potentially significant role in prognosis after RT. The results of our series demonstrate that the presence of high NLR measurements prior to irradiation correlate with poorer treatment outcomes. A possible explanation for this relationship is hypoxia. Hypoxia is not only associated with tumor proliferation, differentiation, and resistance to radiation to radiation and chemotherapy, it also initiates alterations in cytokine expression that cause suppression of immune response, and possibly encouraging an inflammatory response. [53] [54] [55] [56] As solid tumors grow, the supply of oxygen and nutrients eventually become inadequate, leading to tumor necrosis and release of proinflammatory mediates that recruit more inflammatory cells. [1] This cascade toward hypoxia may thus lead to the reduced therapeutic response in patients with high NLR.
A commonly referenced example for inflammation-associated carcinogenesis is the correlation of chronic inflammatory bowel disease and colon cancer. In a review by Terzic´et al, [57] a prevalence of more than 20% of patients with inflammatory bowel disease were observed to develop colitis-associated cancer. Studies of sporadic colorectal cancer at molecular levels have also shown activation of transcription factors that act as important inflammatory pathways, suggesting the potential similarity of extrinsic inflammatory response seen in colitis-associated cancer and intrinsic cytokine recruitment seen in sporadic colorectal cancer. [47] NLR has been suggested to have prognostic value in various solid tumors, but with inconsistent findings. Results of analyses by subsite revealed that high NLR increased the risk of poor OS most in rectal cancers, roughly by 2.5-fold (HR 2.45, 95% CI 1.47 [57] 4.08, P < .001). Elevated baseline NLR demonstrated to have prognostic value for OS and tumor response after neoadjuvant chemoradiation in a retrospective series analyzing 199 locally advanced rectal cancer patients. [32] In this study, multivariate analysis identified that a cut-off value of NLR greater than or equal to 2.8 was an independent factor for poorer OS with a HR of 2.1 (P = .018). This group of patients also showed worse DFS in univariate, but not in multivariate analyses. Hodek et al [34] evaluated 173 local advanced rectal adenocarcinoma patients that underwent neoadjuvant chemoradiation and compared NLR at various threshold values. The authors reported that NLR ranging between 2.2 and 2.8 had significantly better OS and tumor response, but the rate of pathologic CR was not significantly dependent on the pretreatment value of NLR.
Though large amounts of studies emphasizing the potential role of inflammatory parameters are emerging, results continue to be inconsistent across studies due to heterogeneity. With basis on prior documentation on various solid tumors and inflammatory carcinogenesis, NLR may be a useful tool for predicting treatment response especially in disease entities where complete response to treatment can be precisely evaluated. Future studies with larger, homogeneous populations are mandatory for improved assessment of the true role of NLR for predicting clinical outcomes in patients receiving RT.
In conclusion, elevated pretreatment NLR in cancer patients is associated with poorer survival outcomes after RT. The evaluation of NLR prior to oncologic therapy may be a useful and easy-to-obtain parameter for predicting treatment outcomes and selecting a subgroup of patients in need of a more aggressive treatment approach. Further assessment of the basic biologic mechanism behind the prognostic significance of NLR will be needed. Classifying patients with high risks of poor prognosis based on NLR or other similar biologic parameters could play as a stepping stone towards the introduction of targeted therapy to repair or inhibit high NLR, potentially opening a new paradigm for cancer treatment. Our results cannot be conclusive on the magnitude of its usefulness, but could become an elemental basis for future clinical trials for appropriately individualizing RT according to the degree of risks.
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